David Vesco, MD
Adult Medicine · Calabasas, CANPI 1629084074
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 423 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by Amgen at 52.2% of the total. Among adult medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 423 payments — averaging $19.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$4K
- AstraZeneca$1K
- Lilly USA, LLC$625
- Pfizer$360
- Boehringer Ingelheim$311
- Novo Nordisk$282
- plus $1K from 20 others
What the payments were for
- Food & beverage$8,141100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 270 | $4,249 |
| AstraZeneca | 43 | $1,074 |
| Lilly USA, LLC | 29 | $625 |
| Pfizer | 12 | $360 |
| Boehringer Ingelheim | 8 | $311 |
| Novo Nordisk | 13 | $282 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $200 |
| Nestle Healthcare Nutrition Inc. | 2 | $149 |
| Arbor Pharmaceuticals, Inc. | 5 | $115 |
| Johnson & Johnson | 3 | $98 |
| GSK | 3 | $80 |
| Abbott | 3 | $69 |
| Novartis | 3 | $66 |
| AbbVie | 3 | $63 |
| Bausch Health US, LLC | 2 | $59 |
| Indivior Inc. | 2 | $56 |
| Biohaven Pharmaceuticals, Inc. | 3 | $55 |
| Sumitomo Pharma America, Inc. | 2 | $49 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $43 |
| Urovant Sciences Inc | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $25 |
| Lupin Inc. | 1 | $22 |
| Lundbeck LLC | 1 | $19 |
| Azurity Pharmaceuticals, Inc. | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Gilead | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,141 in reported general payments places this provider in the 90th percentile of 221 adult medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 41 | $40,039 |
| FarxigaDapagliflozin Propanediol | 41 | $31,525 |
| Repatha SureclickEvolocumab | 49 | $29,625 |
| OzempicSemaglutide | 21 | $20,029 |
| MounjaroTirzepatide | 15 | $19,558 |
| JardianceEmpagliflozin | 24 | $16,608 |
| XareltoRivaroxaban | 17 | $15,067 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 18 | $7,016 |
| Celecoxib | 48 | $1,469 |
| Nebivolol Hcl | 20 | $947 |
| Gabapentin | 39 | $674 |
| Alcohol Prep PadsAlcohol Antiseptic Pads | 13 | $624 |
| Alprazolam | 86 | $615 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 23 | $608 |
| Memantine Hcl | 17 | $602 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $625 | $59,59756 claims |
| AstraZenecaFarxiga | $1,074 | $31,52541 claims |
| Novo NordiskOzempic | $282 | $20,02921 claims |
| Boehringer IngelheimJardiance | $311 | $16,60824 claims |
| Johnson & JohnsonXarelto | $98 | $15,06717 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor | $115 | $7,01618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 221 adult medicine providers in California.
Other adult medicine in Calabasas
- Susan HutchinsonLaguna Hills$1M
- Natalia GuzmanLos Angeles$583K
- Richard FauselRancho Mirage$30K
- Benedicto EstoestaValley Springs$22K
- Antoine DipsiaW. Sacramento$21K
- Patrick WelchArroyo Grande$20K
- Craig BobsonManteca$19K
- Tin WongLos Angeles$18K
- Sofia VaismanWoodland Hills$13K
- Janja ViltuznikOrange$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.